Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that gemcitabine plus S‐1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared to GC treatments. This study evaluates the efficacy and safety of a modified GS regimen.

中文翻译：

---

吉西他滨和 S-1 在晚期胆道癌患者中的多中心 II 期研究：TG1308 研究。


吉西他滨联合顺铂 (GC) 仍然是晚期胆道癌 (ABTC) 的标准一线治疗方法。 JCOG1113 研究表明，与 GC 治疗相比，吉西他滨加 S-1 (GS) 的中位总生存期并不较差，且中性粒细胞减少症的发生率相当。本研究评估了改良 GS 方案的有效性和安全性。